BioInvent (Sweden)

BioInvent (Sweden)

BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for BioInvent (Sweden), Sweden, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

57%


Total
Publications

102


Total Open
Publications

58


Total
Citations

3.4K


Open Access
Percentage

57%


Total
Publications

102


Total Open
Publications

58


Total
Citations

3.4K

Wikipedia

Website

download

Breakdown

21% 33% 3% 43%

Publisher Open

21%

Both

33%

Other Platform Open

3%

Closed

43%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

012345678910111213Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

38%OA Journal

OA Journal 38%

21

Hybrid 33%

18

No Guarantees 29%

16

Other Platform Open

Domain 78%

29

Institution 49%

18

Public 14%

5

Preprint 8%

3

Other Internet 8%

3

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
29
Europe PMC
Domain
16
University of Southampton - ePrints Soton
Institution
11
Semantic Scholar
Public
4
bioRxiv
Preprint
3
University of Southern Denmark - University of Southern Denmark Research Portal
Institution
2
University of Cambridge - Apollo
Institution
2
University of Bath - University of Bath Research Portal
Institution
2
The University of Manchester - Research Explorer
Institution
2
Radboud University - Radboud Repository
Institution
2
1 / 3

Data updated 13 August 2024

Share

Share

Share